Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024
Utd Therapeut (UTHR.O, NASDAQ Cons)
Závěr k 28.3.2024 Změna (%) Změna (USD) Objem obchodů (ks)
229,72 -5,57 -13,55 1 114 801
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiUnited Therapeutics Corporation
TickerUTHR
Kmenové akcie:Ordinary Shares
RICUTHR.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 1 168
Akcie v oběhu k 14.02.2024 47 058 545
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
Ulice1000 SPRING ST
MěstoSILVER SPRING
PSČ20910
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 016 089 292
Fax13016089291

Business Summary: United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, United Therapeutics Corporation revenues increased 20% to $2.33B. Net income increased 35% to $984.8M. Revenues reflect Orenitram segment increase of 11% to $359.4M, Unituxin segment increase of 9% to $198.9M, United States segment increase of 21% to $2.2B, Rest of World segment increase of 3% to $125.3M. Net income benefited from Interest Income increase from $45.2M to $162.7M (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerMartine Rothblatt6826.06.201601.01.1996
President, Chief Operating OfficerMichael Benkowitz5126.06.201626.06.2016
Chief Financial Officer, TreasurerJames Edgemond55
Executive Vice President, General Counsel, Corporate SecretaryPaul Mahon5901.01.1996